Sociedad Quimica y Minera de Chile Well Positioned Lithium Stock.Bank Stocks – Best Bank Stocks to Invest In.What BlackRock’s Earnings Tell You About The Stock Market Tide.MarketBeat Week in Review – 10/9 – 10/13.Growth Stocks: What They Are, Examples and How to Invest.Five stocks we like better than AVROBIO.Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. Read Our Latest Stock Report on AVROBIO About AVROBIOĪVROBIO, Inc, a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Wells Fargo & Company cut their price target on shares of AVROBIO from $2.50 to $2.00 in a report on Thursday, July 13th. Wedbush cut shares of AVROBIO from an “outperform” rating to a “neutral” rating in a report on Wednesday, July 12th. Several research firms recently issued reports on AVRO. On average, equities research analysts forecast that AVROBIO will post 0.58 earnings per share for the current fiscal year. ![]() The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of $1.35 by ($1.72). Get AVROBIO alerts:ĪVROBIO ( NASDAQ:AVRO – Get Free Report) last issued its earnings results on Thursday, August 10th. ![]() 59.95% of the stock is owned by institutional investors and hedge funds. Finally, Boothbay Fund Management LLC bought a new position in shares of AVROBIO during the second quarter worth about $26,000. FNY Investment Advisers LLC bought a new position in shares of AVROBIO during the first quarter worth about $26,000. Atlas Venture Life Science Advisors LLC now owns 4,541,381 shares of the company’s stock worth $4,541,000 after acquiring an additional 20,518 shares during the last quarter. Atlas Venture Life Science Advisors LLC grew its position in shares of AVROBIO by 0.5% during the first quarter. now owns 45,492 shares of the company’s stock worth $45,000 after acquiring an additional 19,700 shares during the last quarter. grew its position in shares of AVROBIO by 76.4% during the first quarter. Geode Capital Management LLC now owns 343,741 shares of the company’s stock worth $327,000 after purchasing an additional 13,229 shares during the period. ![]() Geode Capital Management LLC raised its holdings in shares of AVROBIO by 4.0% during the second quarter. Institutional Trading of AVROBIOĪ number of institutional investors and hedge funds have recently modified their holdings of the business. Approximately 5.4% of the company’s stock are short sold. Based on an average daily volume of 983,600 shares, the short-interest ratio is presently 2.1 days. As of September 30th, there was short interest totalling 2,100,000 shares, an increase of 21.4% from the September 15th total of 1,730,000 shares. ( NASDAQ:AVRO – Get Free Report) was the target of a significant increase in short interest in September.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |